Terms: = Brain cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
76 results:
1. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
2. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
3. Delivery versus Potency in Treating brain Tumors: BI-907828, a mdm2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma.
Zhang W; Vaubel RA; Oh JH; Mladek AC; Talele S; Zhang W; Waller KL; Burgenske DM; Sarkaria JN; Elmquist WF
Mol Cancer Ther; 2024 Jan; 23(1):47-55. PubMed ID: 37828724
[TBL] [Abstract] [Full Text] [Related]
4. KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated Sarcoma.
Motoi T; Hirata M; Kukita Y; Satomi K; Tamura H; Adachi S; Matsushita Y; Horiguchi SI; Hishima T; Ikegami M; Okuma T; Tao K; Arakawa A; Ogawa C; Matsuda K; Ichimura K; Nakamura H; Mori T; Yoshida A
Mod Pathol; 2023 Nov; 36(11):100317. PubMed ID: 37634866
[TBL] [Abstract] [Full Text] [Related]
5. Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.
Panovska D; Nazari P; Cole B; Creemers PJ; Derweduwe M; Solie L; Van Gassen S; Claeys A; Verbeke T; Cohen EF; Tolstorukov MY; Saeys Y; Van der Planken D; Bosisio FM; Put E; Bamps S; Clement PM; Verfaillie M; Sciot R; Ligon KL; De Vleeschouwer S; Antoranz A; De Smet F
Cell Mol Life Sci; 2023 May; 80(6):147. PubMed ID: 37171617
[TBL] [Abstract] [Full Text] [Related]
6. Expression and Clinical Significance of mdm2 in Non-Functioning PitNETs.
Yao X; Liu Q; Zhao S; Cheng R; Liu C; Zhang G
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837574
[No Abstract] [Full Text] [Related]
7. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract] [Full Text] [Related]
8. BI-907828, a novel potent mdm2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract] [Full Text] [Related]
9. Helicobacter pylori promotes epithelial-to-mesenchymal transition by downregulating CK2β in gastric cancer cells.
Lee SD; Jeong H; Hwang BR; Yu BM; Cho Y; Nam KT; Kim H; Lee YC
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166588. PubMed ID: 36404440
[TBL] [Abstract] [Full Text] [Related]
10. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract] [Full Text] [Related]
11. Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells.
Kıyga E; Adıgüzel Z; Önay Uçar E
Mol Biol Rep; 2022 Sep; 49(9):8701-8713. PubMed ID: 35752701
[TBL] [Abstract] [Full Text] [Related]
12. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.
Wang Q; Li J; Zhu J; Mao J; Duan C; Liang X; Zhu L; Zhu M; Zhang Z; Lin F; Guo R
Clin Transl Med; 2022 Jun; 12(6):e882. PubMed ID: 35692096
[TBL] [Abstract] [Full Text] [Related]
13. Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.
Bonneville-Levard A; Frappaz D; Tredan O; Lavergne E; Corset V; Agrapart V; Chabaud S; Pissaloux D; Wang Q; Attignon V; Cartalat S; Ducray F; Thomas-Maisonneuve L; Honnorat J; Meyronet D; Taillandier L; Blonski M; Viari A; Baudet C; Sohier E; Lantuejoul S; Paindavoine S; Treilleux I; Rodriguez C; Pérol D; Blay JY
Med Oncol; 2021 Nov; 39(1):4. PubMed ID: 34739635
[TBL] [Abstract] [Full Text] [Related]
14. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a mdm2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract] [Full Text] [Related]
15. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract] [Full Text] [Related]
16. miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/mdm2 feedback loop.
Chen Q; Wang W; Chen S; Chen X; Lin Y
Cell Mol Biol Lett; 2021 May; 26(1):21. PubMed ID: 34044759
[TBL] [Abstract] [Full Text] [Related]
17. FMR1/circCHAF1A/miR-211-5p/HOXC8 feedback loop regulates proliferation and tumorigenesis via mdm2-dependent p53 signaling in GSCs.
Jiang Y; Wang Z; Ying C; Hu J; Zeng T; Gao L
Oncogene; 2021 Jun; 40(24):4094-4110. PubMed ID: 34017077
[TBL] [Abstract] [Full Text] [Related]
18. mdm2 induces EMT via the B‑Raf signaling pathway through 14‑3‑3.
Ou M; Xu X; Chen Y; Li L; Zhang L; Liao Y; Sun W; Quach C; Feng J; Tang L
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 33955525
[TBL] [Abstract] [Full Text] [Related]
19. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo.
Huang H; Park S; Zhang H; Park S; Kwon W; Kim E; Zhang X; Jang S; Yoon D; Choi SK; Yi JK; Kim SH; Dong Z; Lee MH; Ryoo Z; Kim MO
J Exp Clin Cancer Res; 2021 Mar; 40(1):114. PubMed ID: 33785035
[TBL] [Abstract] [Full Text] [Related]
20. Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Menyhárt O; Fekete JT; Győrffy B
Carcinogenesis; 2021 Jun; 42(6):804-813. PubMed ID: 33754151
[TBL] [Abstract] [Full Text] [Related]
[Next]
